血友病A的因子替代治疗:成就和前景
1Department of Cardiovascular Diseases, Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Seminars in thrombosis and hemostasis
|October 14, 2024
概括
延长半衰期 (EHL) 第八因子 (FVIII) 疗法改善了血友病A的预防,减少了注射频率并提高了患者的生活质量. 新的超长期作用的EHL FVIII提供了更大的保护和改善关节健康.
科学领域:
- 血液学 血液学 血液学
- 药理动力学 药理动力学
- 基因治疗 基因治疗
背景情况:
- 在血友病A (PwHA) 中严重出血的表型需要预防.
- 原生因子VIII (FVIII) 需要频繁的静脉注射,导致治疗负担和不良坚持.
- 延长半衰期 (EHL) FVIII分子提供了改善的预防和治疗个性化.
研究的目的:
- 审查PwHA的FVIII替代疗法的成果和前景.
- 讨论EHL FVIII对预防和患者结果的影响.
- 为了突出超长效应的EHL FVIII疗法的进展.
主要方法:
- 对EHL FVIII分子的临床开发计划的审查.
- 在PwHA中对EHL FVIII使用的现实数据的分析.
- 讨论增强FVIII药物动力学特性的技术 (例如,Fc融合,PEGylation).
主要成果:
- 在PwHA中,EHL FVIII已经证明了显著的益处,改善了预防的可行性和结果.
- Fc融合和PEGylation技术增强了FVIII PK概况,使剂量更少.
- 超长期作用的EHL FVIII显示出接近正常的血液静止和改善关节健康的承诺.
结论:
- EHL FVIII疗法在A型血友病的治疗方面取得了重大进展.
- 用EHL FVIII进行个性化预防改善了坚持,关节健康和生活质量.
- 未来的超长效应EHL FVIII疗法旨在提供对出血事件的近乎完整的保护.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
633
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
633
Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
Disorders of Hemostasis
737
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
737
Blood Transfusion and Agglutination
10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K
Extrinsic and Intrinsic Pathways of Hemostasis
6.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.1K
Recombinant DNA
93.3K
Overview
93.3K


